Global Biosimilar Markets: Europe vs United States (2026 Analysis)

Pharmaceutical costs are a massive headache for healthcare systems worldwide. For years, the answer was supposed to be biosimilars, which are biologic medical products highly similar to an already approved reference biologic product with no clinically meaningful differences in safety, purity, and potency. But if you look at the data from 2024 and early 2026, something strange happens when you compare the two biggest players: Europe and the United States. Europe started first, built a mature ecosystem, and is now seeing steady growth. The US had a rocky start but is currently sprinting ahead with aggressive growth projections. Why does this divergence exist, and where is the money actually going?

The Core Difference: Timing and Regulation

To understand the current landscape, you have to look back at the starting line. The European Medicines Agency (EMA) established the world's first regulatory framework for biosimilars in 2006. They approved Omnitrope that same year. This gave Europe a nearly decade-long head start. By the time the US passed the Biologics Price Competition and Innovation Act (BPCIA) in 2009, Europe was already figuring out how doctors and patients reacted to these new drugs.

The US didn't approve its first biosimilar, Zarxio, until March 2015. That five-year gap between legislation and approval created a "biosimilar void" that allowed originator companies to maintain high prices without competition for much longer than in Europe. According to IQVIA's 2024 assessment, this delay meant that by 2024, only 12 biosimilars were launched in the US compared to over 100 approved in Europe since 2006. The difference isn't just about speed; it's about building a culture of trust among physicians and payers.

Market Size and Growth Trajectories

When you crunch the numbers, the picture gets even more interesting. Market sizing varies depending on who you ask, but the trends are clear. In 2024, the European biosimilars market generated roughly USD 9.9 billion to USD 13.16 billion, depending on whether you follow Grand View Research or Precedence Research. It grew at a compound annual growth rate (CAGR) of 13% from 2020 to 2024.

The US market hit USD 10.9 billion in 2024, according to Alira Health, growing at an 11% CAGR from 2020. While Europe has historically held a larger share, the US is accelerating faster. IMARC Group projects the US market will reach USD 30.2 billion by 2033 at a CAGR of 18.5%. Meanwhile, Europe is projected to grow to USD 64.82 billion by 2034 at a slightly lower CAGR of 17.34%. North America is expected to lead regional market revenue by 2027, signaling a major shift in global power dynamics.

Regulatory Hurdles: The Switching Study Debate

One of the biggest friction points in the US market has been the concept of "interchangeability." To get this designation, which allows pharmacists to substitute a biosimilar for the reference product without the prescriber's intervention, the FDA historically required extensive switching studies. These studies proved that alternating between the biosimilar and the original drug didn't cause safety issues.

This requirement created a massive barrier. It was expensive, time-consuming, and scientifically debated. Dr. Rachel Sherman of the FDA's Center for Drug Evaluation and Research acknowledged this in June 2024, stating that previous requirements created unnecessary barriers. Consequently, the FDA proposed new guidelines eliminating the need for switching studies to achieve interchangeable designation. This move aligns the US closer to the European model, which relies on a "totality-of-evidence" approach requiring limited clinical data. As Dr. Hans-Georg Eichler of the EMA noted, robust scientific evaluation coupled with clear communication is more effective than extensive trials for demonstrating biosimilarity.

Adoption Drivers: Procurement vs. Fragmentation

Why did Europe adopt biosimilars so quickly? It comes down to system structure. European countries implemented structured pricing and substitution policies early on. Hospital tenders, particularly in Germany, France, and the UK, accelerated uptake. Dr. Marc Grégoire of Fresenius Kabi pointed out that European hospital procurement systems and mandatory substitution policies created ideal conditions for rapid uptake.

In contrast, the US healthcare system is fragmented. You have Medicare, Medicaid, private insurers, pharmacy benefit managers (PBMs), and independent pharmacies all making different decisions. This complexity slowed adoption. However, the Inflation Reduction Act of 2022 changed the game. By eliminating the Medicare Part D coverage gap and providing incentives for biosimilar adoption, the US government began pushing providers toward cheaper alternatives. Dr. Sarah Toner of the IQVIA Institute highlighted this as a significant catalyst for recent US market growth.

Therapeutic Focus and Patent Cliffs

The types of drugs also differ. Europe excels in oncology and rheumatology, where biosimilars have achieved over 80% market share in some countries for monoclonal antibodies used in autoimmune diseases. The US initially saw stronger adoption in supportive care products like filgrastim (colony-stimulating factors).

Now, the US is catching up in complex therapeutic areas thanks to massive patent expirations. Between 2025 and 2034, 118 biologics are expected to lose patent protection, presenting a $232 billion opportunity according to IQVIA. A prime example is Humira (adalimumab). As of 2024, 14 Humira biosimilars were approved in the US, though only 6 were commercially available due to patent settlements. This "patent thicket" strategy by originator companies delayed competition but is finally unraveling.

Manufacturing Powerhouses

Who makes these drugs? Europe, and specifically Germany, has emerged as a manufacturing powerhouse. Companies like Sandoz (Novartis), Fresenius Kabi, and Amgen have strong footholds there. The strategic position in the value chain attracts global developers. In the US, players like Pfizer, Merck, and Samsung Bioepis are driving innovation. As regulatory harmonization improves, we're seeing more cross-border collaboration, but local manufacturing capabilities remain a key competitive advantage for each region.

Future Outlook: Convergence and Cost Savings

Looking ahead to 2030 and beyond, the lines between the two markets are blurring. The FDA's regulatory shifts mirror the EMA's pragmatic approach. Both regions face challenges with next-generation biologics, which are harder to manufacture and require more rigorous validation. However, the long-term trajectory is positive. Biosimilars are projected to drive substantial healthcare cost savings, typically launching at 15-30% discounts compared to reference products. With North America potentially overtaking Europe in market size by 2027, the focus is shifting from "if" biosimilars will succeed to "how fast" they can penetrate remaining high-cost markets in immunology and endocrinology.